Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
OncoTargets and Therapy
Volume 14, 2021 - Issue
Case Report
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report
, , & 
Yuankai Shi1 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-3342-4964View further author information
https://orcid.org/0000-0002-3342-4964View further author information